产品
编 号：F168256
分子式：C51H40N6O23S6
分子量：1297.28
分子式：C51H40N6O23S6
分子量：1297.28
产品类型
规格
价格
是否有货
结构图
CAS No: 145-63-1
产品详情
生物活性：
Suramin is a reversible and competitive protein-tyrosine phosphatases (PTPases) inhibitor. Suramin is a potent inhibitor of sirtuins: SirT1 (IC50=297 nM), SirT2 (IC50=1.15 μM), and SirT5 (IC50=22 μM). Suramin is a competitive inhibitor of reverse transcriptase (DNA topoisomerase II: IC50=5 μM). Suramin is a potent SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) inhibitor.Suramin efficiently inhibits IP5K and is an antiparasitic, anti-neoplastic and anti-angiogenic agent.
体内研究：
Suramin (10 mg/kg; IV; twice weekly for 3 weeks) reverses established pulmonary hypertension (PH), thereby normalizing the pulmonary artery pressure values and vessel structure.Animal Model:Adult male Wistar rats (200-225 g)
Dosage:10 mg/kg
Administration:IV; twice weekly for 3 weeks
Result:Reversed established PH, thereby normalizing the pulmonary artery pressure values and vessel structure.
体外研究：
Suramin (50-600 μg/mL; for 24-96 hours) inhibits cells proliferation in a dose-dependent and time-dependent manner and decreases viability in cancer cells. Suramin (300 μg/mL; for 48 hours) induces cells apoptosis, and down-regulates mRNA expression in HeLa cells. Suramin (1 mg/mL; 1 hour) significantly suppresses the phosphorylated ERK1/2. The IC50 values of HO-8910 PM and HeLa are 319 μg/mL, 476 μg/mL, respectively. Suramin blocks viral replication in Vero E6 cells.
Suramin is a reversible and competitive protein-tyrosine phosphatases (PTPases) inhibitor. Suramin is a potent inhibitor of sirtuins: SirT1 (IC50=297 nM), SirT2 (IC50=1.15 μM), and SirT5 (IC50=22 μM). Suramin is a competitive inhibitor of reverse transcriptase (DNA topoisomerase II: IC50=5 μM). Suramin is a potent SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) inhibitor.Suramin efficiently inhibits IP5K and is an antiparasitic, anti-neoplastic and anti-angiogenic agent.
体内研究：
Suramin (10 mg/kg; IV; twice weekly for 3 weeks) reverses established pulmonary hypertension (PH), thereby normalizing the pulmonary artery pressure values and vessel structure.Animal Model:Adult male Wistar rats (200-225 g)
Dosage:10 mg/kg
Administration:IV; twice weekly for 3 weeks
Result:Reversed established PH, thereby normalizing the pulmonary artery pressure values and vessel structure.
体外研究：
Suramin (50-600 μg/mL; for 24-96 hours) inhibits cells proliferation in a dose-dependent and time-dependent manner and decreases viability in cancer cells. Suramin (300 μg/mL; for 48 hours) induces cells apoptosis, and down-regulates mRNA expression in HeLa cells. Suramin (1 mg/mL; 1 hour) significantly suppresses the phosphorylated ERK1/2. The IC50 values of HO-8910 PM and HeLa are 319 μg/mL, 476 μg/mL, respectively. Suramin blocks viral replication in Vero E6 cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备